What Is Semaglutide? How It Works for Weight Loss

Semaglutide Weight Loss

15-17% body weight lost

In the STEP 1 trial, adults with obesity lost an average of 14.9% of body weight over 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo.

Wilding et al., NEJM, 2021

Wilding et al., NEJM, 2021

View as image

Semaglutide is a synthetic peptide that mimics glucagon-like peptide-1 (GLP-1), a hormone your gut produces after eating. Natural GLP-1 lasts about 2 minutes in the bloodstream before enzymes destroy it. Semaglutide is engineered to last about a week. That single change, extending the hormone's lifespan from minutes to days, turned a biological curiosity into the most commercially successful weight loss drug in history. This article covers what semaglutide is, the specific mechanisms behind its weight loss effects, and what the clinical data actually shows. For the broader weight loss evidence, see the pillar article on semaglutide for weight loss without diabetes.

What Semaglutide Is: A Modified Version of a Natural Hormone

GLP-1 is produced by L-cells in the intestinal wall in response to food. It signals the pancreas to release insulin, suppresses glucagon from alpha cells, slows gastric emptying, and activates satiety circuits in the brain. The problem with natural GLP-1 as a drug is that dipeptidyl peptidase-4 (DPP-4) enzymes break it down within 1-2 minutes of secretion.^[1]

Semaglutide solves this through three structural modifications to the native GLP-1 peptide:

1. An amino acid substitution at position 8 (alanine to alpha-aminoisobutyric acid) that blocks DPP-4 cleavage
2. An amino acid substitution at position 34 (lysine to arginine) that directs fatty acid attachment to the correct location
3. A C-18 fatty diacid chain attached via a linker to position 26, which enables binding to albumin in the blood

The albumin binding is the critical innovation. When semaglutide binds to circulating albumin, it becomes too large for kidney filtration and too protected for enzymatic degradation. This extends the half-life from 2 minutes to approximately 165 hours (about 7 days), allowing once-weekly dosing.^[7]

Papakonstantinou and Tsioufis published a 2024 review detailing semaglutide's mechanism of action, confirming that the drug activates the same receptor as natural GLP-1 but with sustained rather than pulsatile signaling.^[3] This continuous activation produces qualitatively different effects than the brief post-meal GLP-1 bursts the body normally experiences. For the full history of how this drug class developed from Gila monster venom, see the history of GLP-1 drugs.

How Semaglutide Produces Weight Loss: Three Mechanisms

Brain: Reducing Appetite and Food Reward

Semaglutide crosses the blood-brain barrier (partially) and activates GLP-1 receptors in the hypothalamus and brainstem, two regions central to appetite regulation. Gibbons, Blundell, and colleagues demonstrated in a 2021 study that oral semaglutide reduced ad libitum energy intake by approximately 35%, with participants reporting less hunger, fewer food cravings, and reduced desire to eat high-fat foods.^[8]

The appetite reduction involves multiple brain circuits:

• Area postrema and nucleus tractus solitarius (brainstem): receive direct hormonal signals, initiate meal termination
• Arcuate nucleus (hypothalamus): home to POMC/CART neurons (appetite-suppressing) and AgRP/NPY neurons (appetite-stimulating); semaglutide activates the former and suppresses the latter
• Mesolimbic reward system: GLP-1 receptors in the ventral tegmental area and nucleus accumbens reduce the rewarding properties of food

This brain-mediated appetite reduction is the primary driver of weight loss. Patients eat less because they feel full sooner and find food less compelling, not because of nausea or gastrointestinal discomfort (though those side effects also reduce intake temporarily during dose escalation).

Ghidewon and colleagues identified an additional mechanism in 2022: semaglutide increases circulating levels of growth differentiation factor 15 (GDF15), a stress-response protein that independently suppresses appetite through brainstem signaling.^[9] Whether GDF15 elevation contributes meaningfully to weight loss or is an epiphenomenon remains under investigation.

Gut: Slowing Gastric Emptying

Semaglutide delays the rate at which food moves from the stomach into the small intestine. This produces a prolonged sensation of fullness after meals and slows glucose absorption, reducing post-meal blood sugar spikes.^[3]

The gastric slowing effect is most pronounced in the first weeks of treatment and partially attenuates over time (a phenomenon called tachyphylaxis). This is consistent with the observation that nausea, the most common side effect, is worst during dose escalation and improves with continued use.

Pancreas: Glucose-Dependent Insulin Enhancement

Semaglutide stimulates insulin secretion from pancreatic beta cells, but only when blood glucose is elevated. This glucose-dependent mechanism means semaglutide does not cause hypoglycemia when used alone (unlike sulfonylureas or exogenous insulin). It also suppresses inappropriate glucagon secretion from alpha cells, reducing hepatic glucose output after meals.^[1]

While these pancreatic effects are central to semaglutide's diabetes indication, they play a supporting role in weight loss. The metabolic improvements (lower insulin resistance, better glucose handling) likely facilitate fat mobilization, but the appetite reduction is the dominant weight loss mechanism.

What the Clinical Trials Show

STEP 1: The Landmark Obesity Trial

Wilding and colleagues published the pivotal STEP 1 trial in the New England Journal of Medicine in 2021.^[2] Key results from 1,961 adults with obesity (BMI 30+ or 27+ with comorbidities):

• Mean weight loss: 14.9% with semaglutide vs 2.4% with placebo at 68 weeks
• 86.4% of semaglutide patients lost at least 5% body weight (vs 31.5% placebo)
• 69.1% lost at least 10% (vs 12.0%)
• 50.5% lost at least 15% (vs 4.9%)
• Mean absolute weight change: approximately 15.3 kg (33.7 lbs) with semaglutide

For detailed weight loss outcomes, see how much weight can you lose on semaglutide.

STEP 5: Two-Year Durability

Garvey and colleagues followed 304 participants for 104 weeks (2 years) in the STEP 5 trial.^[4] Results showed that weight loss was maintained with continued treatment: 15.2% at 104 weeks compared to 2.6% with placebo. The weight loss curve plateaued at approximately 60 weeks and remained stable through the end of the trial.

Weight Regain After Stopping

Rubino and colleagues examined what happens after discontinuation in the STEP 1 extension study.^[5] One year after stopping semaglutide, participants had regained approximately two-thirds of the weight they lost. They also showed worsening of cardiometabolic risk factors (blood pressure, lipids, HbA1c) that had improved during treatment. This finding established that semaglutide treats obesity rather than curing it, requiring continued use to maintain benefits. See what happens when you stop taking semaglutide for a deeper analysis.

Side Effects Profile

Wharton and colleagues published a pooled analysis of GI tolerability across the STEP program in 2022.^[6] The most common adverse events:

• Nausea: 44% (vs 17% placebo), mostly mild to moderate, peaking during dose escalation
• Diarrhea: 30% (vs 16% placebo)
• Vomiting: 24% (vs 6% placebo)
• Constipation: 24% (vs 11% placebo)

Discontinuation due to GI side effects occurred in about 7% of semaglutide patients. The slow dose escalation schedule (starting at 0.25 mg and increasing monthly to the target dose of 2.4 mg) was specifically designed to mitigate these effects. For dosing details, see semaglutide dose escalation.

Brand Names: Same Drug, Different Doses and Indications

Semaglutide is sold under three brand names:

• Ozempic (injectable, 0.5-2.0 mg weekly): approved for type 2 diabetes
• Wegovy (injectable, 2.4 mg weekly): approved for chronic weight management
• Rybelsus (oral tablets, 7-14 mg daily): approved for type 2 diabetes

The difference between Ozempic and Wegovy is the dose and the approved indication, not the molecule. They contain identical semaglutide. For a detailed comparison, see Ozempic vs Wegovy.

Semaglutide vs Other GLP-1 Drugs

Semaglutide is not the only GLP-1 receptor agonist, but it produces more weight loss than earlier drugs in the class. Rubino and colleagues showed in a head-to-head trial that semaglutide 2.4 mg produced 15.8% weight loss versus 6.4% for liraglutide 3.0 mg (Saxenda) over 68 weeks.^[10]

Tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 agonist, has shown weight loss of 20-26% in clinical trials, surpassing semaglutide. For that comparison, see tirzepatide vs semaglutide. For a broader class overview, see every GLP-1 receptor agonist compared.

Effects Beyond Weight: What Else Semaglutide Does

O'Neil and colleagues analyzed the "wider benefits" of semaglutide across the STEP program in 2022, documenting improvements that extended beyond the scale.^[11]

Cardiovascular risk factors improved consistently: systolic blood pressure dropped by 6-7 mmHg, waist circumference decreased by 13-14 cm, and C-reactive protein (an inflammation marker) fell by approximately 50%. Triglycerides, LDL cholesterol, and HbA1c all improved in proportion to weight loss.

Physical function scores improved in patients with obesity and knee osteoarthritis. Participants reported reduced joint pain and better mobility, likely driven by the mechanical benefit of carrying less weight rather than a direct pharmacological effect.

Quality of life metrics (measured by the SF-36 and IWQOL-Lite questionnaires) showed improvements in physical functioning, bodily pain, vitality, and mental health domains. Whether these reflect the weight loss itself or the psychological impact of successful treatment is difficult to separate.

Amaro and colleagues published a complementary analysis of the STEP evidence in 2022, noting that semaglutide produced clinically meaningful improvements in nearly every cardiometabolic parameter measured, with the magnitude of improvement generally correlating with the degree of weight loss.^[12]

These findings contributed to Novo Nordisk conducting the SELECT cardiovascular outcomes trial, which demonstrated that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with obesity and established cardiovascular disease.

What Remains Unclear

The brain mechanisms behind semaglutide's appetite effects are not fully mapped. Which GLP-1 receptor populations in the brain contribute most to weight loss (brainstem vs. hypothalamus vs. reward circuits) is still being investigated. Whether the drug directly crosses the blood-brain barrier or signals indirectly through vagal afferents is debated.

Long-term safety data beyond 2 years is limited for the weight management indication. Thyroid C-cell tumors were observed in rodent studies at high doses; human relevance has not been established, but the FDA black box warning remains.

Body composition changes during semaglutide-induced weight loss include some lean mass loss alongside fat loss. The clinical significance of this, and whether exercise or protein intake can mitigate it, is an active area of research. See does semaglutide change your body composition.

The Bottom Line

Semaglutide is a modified version of the natural GLP-1 hormone, engineered for a one-week half-life through fatty acid acylation and amino acid substitutions. It produces weight loss primarily by reducing appetite through brain GLP-1 receptor activation, with additional contributions from delayed gastric emptying and improved glucose metabolism. Clinical trial data shows consistent 15-17% body weight loss over 68 weeks, maintained with continued treatment but largely reversible upon discontinuation. GI side effects are common but manageable through dose escalation.

Frequently Asked Questions

What is semaglutide and how does it work?

Semaglutide is a synthetic peptide that mimics GLP-1, a hormone your gut produces after eating. It has been engineered with a fatty acid chain that extends its half-life from 2 minutes to about 1 week. It works by activating GLP-1 receptors in the brain (reducing appetite), gut (slowing gastric emptying), and pancreas (enhancing insulin secretion). The appetite reduction through brain signaling is the primary mechanism behind its weight loss effects.

How much weight can you lose on semaglutide?

In the STEP 1 clinical trial (1,961 participants), the average weight loss was 14.9% of body weight over 68 weeks on semaglutide 2.4 mg, compared to 2.4% on placebo. About half of participants lost 15% or more. Individual results vary based on starting weight, dose adherence, diet, and physical activity. The STEP 5 trial showed this loss was maintained at 2 years with continued use.

Is semaglutide the same as Ozempic?

Semaglutide is the active ingredient in three FDA-approved brand name drugs: Ozempic (injectable, for type 2 diabetes at doses up to 2.0 mg weekly), Wegovy (injectable, for weight management at 2.4 mg weekly), and Rybelsus (oral tablets, for type 2 diabetes). The molecule is identical across all three; the differences are dose, formulation, and approved indication.

Do you regain weight after stopping semaglutide?

Yes. In the STEP 1 extension study, participants regained approximately two-thirds of their lost weight within one year of stopping semaglutide. Cardiometabolic improvements (blood pressure, cholesterol, blood sugar) also reversed. This indicates semaglutide manages obesity as a chronic condition rather than providing a permanent cure.

What are the most common side effects of semaglutide?

Gastrointestinal effects are the most common: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) based on pooled STEP trial data. These are mostly mild to moderate, peak during the dose escalation period, and improve with continued use. About 7% of patients discontinue treatment due to GI side effects. Serious adverse events are rare.

How is semaglutide different from tirzepatide?

Semaglutide activates only the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors (dual agonism). In clinical trials, tirzepatide has produced greater weight loss (20-26%) than semaglutide (15-17%). Both are injectable peptide drugs given once weekly. They have similar side effect profiles, with GI symptoms being the most common for both.